Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbenicillin Indanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 1/20 | 0.56 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbenicillin Indanyl SCHEMBL11311104 | 1.00 | KDM4E (0.56) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL22818119 | 1.00 | KDM4E (0.56) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL33857 | 0.99 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL11309244 | 0.99 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL29592774 | 0.99 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL33855 | 0.99 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL4936924 | 0.99 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL10741454 | 0.99 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL1736359 | 0.98 | PTGS1 (0.55) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL15668574 | 0.97 | PTGS1 (0.56) | KDM4ERECQLTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| CN-105492004-A | Method of treating topical microbial infections | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| CN-105492005-A | Methods of treating microbial infections including mastitis | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| CN-104825397-A | Controlled release delivery device containing organosol coating | ISA ODIDI | 2015-08-12 | — | — | CN | claimed |
| WO-2014121342-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA PTY LIMITED (AU) | 2014-08-14 | — | — | WO | claimed |
| CN-101744760-A | Sustained release carrier for difficult soluble or easy decomposable drug | ZHIWEN JIANG | 2010-06-23 | — | — | CN | claimed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | claimed |
| CN-101553210-A | Method and system for delivering a drug via inhalation | NEXT SAFETY INC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | claimed |
| CN-101094658-A | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form | FLAMEL TECH SA (FR) | 2007-12-26 | — | — | CN | claimed |
| CN-101014340-A | Pharmaceutical formulation based on antibiotic in microcapsule form | FLAMEL TECH SA (FR) | 2007-08-08 | — | — | CN | claimed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-11491105-B2 | Methods of treating microbial infections, including mastitis | Luoda Pharma Limited (IE) | 2022-11-08 | — | — | US | disclosed |
| EP-0009425-B1 | NOVEL NAPHTYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1982-01-27 | — | — | EP | disclosed |
| EP-0009425-A1 | Novel naphtyridine derivatives and pharmaceutical compositions containing them | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | KDM4E 4283/4885RECQL 3373/4885TDP1 3972/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | KDM4E 3688/4885RECQL 4575/4885TDP1 4845/4885 |
| US-11491105-B2 | Methods of treating microbial infections, including mastitis | LCT, TSLP, MLEC | KDM4E 3688/4885RECQL 4575/4885TDP1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.